durvalumab subcutaneous (MEDI4736 SC) / AstraZeneca - LARVOL DELTA

Refractory Gastrointestinal Dysmotility From Anti-Hu / Antineuronal Nuclear Antibody-Type 1 Paraneoplastic Syndrome: A Cause of Enteral Feeding Failure (ACG 2026) - "Case Description/ A 68-year-old woman with recently diagnosed SCLC treated with cisplatin, etoposide and durvalumab presented with subacute progressive neurologic decline including encephalopathy, peripheral neuropathy, autonomic dysfunction, and severe dysphagia requiring percutaneous endoscopic gastrostomy (PEG) tube placement to maintain adequate nutrition. Figure: Figure 2. Axial computed tomography of the abdomen demonstrating the percutaneous endoscopic gastrostomy (PEG) tube in appropriate intragastric position without gastric distention or radiographic evidence of proximal obstruction."

CNS Disorders • Gastrointestinal Disorder • Infectious Disease • Lung Cancer • Pneumonia • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor

Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study. (PubMed, Clin Cancer Res) - P1 | "MEDI1191 and durvalumab were tolerated. Preliminary antitumor activity was encouraging in these heavily pretreated patients, including patients previously treated with immune checkpoint inhibitors."

First-in-human • Journal • P1 data • Oncology • Solid Tumor • IL12A

Paraneoplastic Neurological Syndrome in a Patient with Limited-stage Small-cell Lung Cancer Receiving Durvalumab Maintenance after Concurrent Chemoradiotherapy: A Case Report. (PubMed, Intern Med) - "No neurological worsening or severe immune-related adverse events occurred during approximately one year of durvalumab maintenance therapy, and the tumor response was sustained. Durvalumab maintenance after cCRT may be feasible in carefully selected patients with LS-SCLC and clinically stable pre-existing PNS and residual neurological deficits, under close multidisciplinary monitoring."

Journal • CNS Disorders • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

CT-Based Integrated Body Phenotyping Captures Host Susceptibility to Radiation Pneumonitis in Locally Advanced NSCLC (IASLC-WCLC 2026) - "Methods : Pre-treatment CT scans for patients receiving CRT for LA-NSCLC on the RTOG 0617 trial (n=453) and CRT followed by durvalumab per the PACIFIC regimen at Memorial Sloan Kettering Cancer Center (MSKCC, n=224) were retrospectively analyzed. Conclusions : CT-derived tissue features extracted via a high-throughput, automated deep-learning pipeline predicted high-grade radiation pneumonitis in patients with LA-NSCLC treated with CRT +/- immunotherapy. These findings position multi-organ CT imaging as a noninvasive sensor of systemic host biology, enabling quantification of individual susceptibility to treatment-related toxicity and complementing existing risk stratification frameworks to identify patients who may benefit from individualized dose optimization, more frequent monitoring, and prophylactic or alternative treatment strategies."

Metastases • Inflammation • Lung Cancer • Non Small Cell Lung Cancer • Pneumonia • Solid Tumor

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; camizestrant for breast cancer, ivosidenib for biliary tract cancer, subcutaneous isatuximab and talquetamab plus teclistamab for multiple myeloma, isotretinoin for neuroblastoma, selpercatinib for pediatric RET-altered tumors, tafasitamab for lymphoma, and tislelizumab and durvalumab for... (PubMed, Int J Clin Oncol) - No abstract available

Japanese regulatory • Journal • Biliary Cancer • Biliary Tract Cancer • Breast Cancer • Gastric Cancer • Hematological Malignancies • Lymphoma • Multiple Myeloma • Neuroblastoma • Oncology • Pediatrics • Solid Tumor

Network meta-analysis of immune checkpoint inhibitors in BCG-naïve, high-risk non-muscle-invasive bladder cancer. (PubMed, Urol Oncol) - "In this NMA, durvalumab plus BCG and sasanlimab plus BCG significantly reduced events vs. BCG alone (HR 0.68 each), whereas atezolizumab plus BCG did not (HR 0.98; 95% CI 0.71-1.36). Pairwise indirect comparisons between active regimens were not statistically significant; point estimates and P-scores are consistent with a 2-tier efficacy pattern but do not establish between-agent differences. CIS-stratified subgroup analyses are exploratory and require confirmation."

Checkpoint inhibition • Journal • Retrospective data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Development of ex vivo models to study the response to immunotherapy in hepatocellular carcinoma (EASL 2026) - "These results suggest that this system could be useful to identify responding patients and to characterize mechanisms associated with response to ICI."

Preclinical • Hepatocellular Cancer • Oncology • Solid Tumor • CD8 • IFNG • PTPRC

Dual Immune-Mediated Endocrinopathies Following Checkpoint Blockade: A Case Report (ENDO 2026) - "Tremelimumab (anti-CTLA-4) and durvalumab (anti-PD-L1) combination therapy can rarely induce both thyroiditis and type 1 diabetes mellitus as immune-related adverse events. Thyroiditis occurs in ~1.5% of patients receiving this therapy. The overall incidence of type 1 diabetes is ~0.2–1.9%, with combination therapy conferring higher risk than monotherapy."

Case report • Checkpoint block • Checkpoint inhibition • Clinical • Cardiovascular • Endocrine Disorders • Hepatocellular Cancer • Hypertension • Metabolic Disorders • Solid Tumor • Type 1 Diabetes Mellitus

Impact of dual immune checkpoint blockade on the tumor immune microenvironment and determinants of therapeutic response in hepatocellular carcinoma (EASL 2026) - "Background and aims: Dual immune checkpoint blockade (durvalumab plus tremelimumab) improves outcomes in advanced hepatocellular carcinoma, but treatment-induced microenvironmental changes and determinants of resistance remain incompletely understood. Dual immune checkpoint blockade promotes intratumoral T-cell infiltration and antitumor activity. Tumor barcoding and functional validation implicate an MCL1-associated program as a potential mediator of resistance in hepatocellular carcinoma, which may be associated with suppression of CD4+ T cells."

Checkpoint block • Checkpoint inhibition • IO biomarker • Hepatocellular Cancer • Oncology • Solid Tumor • CD4 • CD8 • FOXP3 • MCL1

ASSESSING DISTRIBUTION OF SOCIAL AND PRIVATE VALUE CREATION BY DRUGS REGULATING PROGRAMMED CELL DEATH-1IN CANCER TREATMENT... (ISPOR 2026) - "Pembrolizumab generated a positive net health value ($14.3B), as did cemiplimab ($.86B) and dostarlimab ($.03B). Negative net health value was generated by nivolumab (-$5.1B), atezolivumab (-$4.4B), avelumab (-$.064B), and durvalumab (-$5.9B). PD-1 drugs created substantial social and private value, with evident variation by drug indication and lifecycle. These findings provide a basis for assessing the return on both public and private investments and evidence-based policy regarding drug pricing and innovation."

Oncology

Keratoacanthoma-like Scalp Metastases from the Squamous Component of Pulmonary Adenosquamous Carcinoma: A Case Report (EADO 2026) - "The patient was receiving systemic oncologic treatment with durvalumab and domvanalimab. The absence of epidermal involvement and supportive immunohistochemical findings were key to establishing the metastatic nature of the lesions. Dermatologists should maintain a high index of suspicion for cutaneous metastases when evaluating rapidly growing scalp nodules in patients with known internal malignancies."

Case report • Clinical • Lung Cancer • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • NKX2-1

Small cell lung cancer humanized mouse models identifies unique T cell infiltration immune phenotypes in response to combination immune-radiation therapies. (AACR 2026) - "We further characterized SCLC hu-mice for their ability to model therapeutic sensitivity, focusing on a novel triplet regimen, AZD1390 (ATM inhibitor) with radiotherapy (RT) and durvalumab (aPDL1), to investigate how DNA damage repair inhibition plus RT can reshape the immune microenvironment and sensitize SCLC subtypes to aPDL1. Immunodeficient mice were intravenously injected with human PBMCs and subcutaneously engrafted with a panel of human SCLC cell-lines corresponding to all subtypes. Our preclinical observations demonstrate PBMC hu-mice as a viable platform to model intrinsic immune-tumor characteristics of engrafted human SCLC cell-lines. Combinatory radiation therapy enhanced anti-PDL1 efficacy in select models. Future studies will aim to identify response-defining features of treated models to improve patient selection in clinical trials."

IO biomarker • Preclinical • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • ASCL1 • CD8 • CGAS • CXCL10 • ENTPD1 • IFNG • ITGAE • NEUROD1 • POU2F3 • STING

Preclinical Characterization of ALG-094295, a highly potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor targeting dimerization, internalization and degradation of PD-L1 (AACR 2026) - "In a humanized PD-L1 MC38 mouse model, a single oral dose of ALG-094295 (5 mg/kg) achieved PD-L1 target engagement comparable to INCB086550 (150 mg/kg PO). Daily oral dosing of ALG-094295 (50 or 150 mg/kg) in humanized PD-L1 MC38 mice over 21 days resulted in tumor growth inhibition equivalent to twice-weekly administration of durvalumab (10 mg/kg IV), with tumor size correlating with increased CD8⁺ T-cell infiltration... ALG-094295 is a highly potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor that promotes PD-L1 dimerization, internalization and degradation. ALG-094295 has the potential to overcome some limitations of antibody-based therapies due to potent PD-L1 blockade, oral delivery and novel mechanism of action."

Preclinical • Oncology • CD8

IMFINZI-subQ: A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

D907HC00001: A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab. (clinicaltrialsregister.eu) - P1 | N=4 | Not yet recruiting | Sponsor: AstraZeneca AB

New P1 trial • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • EGFR

Adapting radiotherapy to cancer immunotherapy (AACR 2025) - "Success in either case has been demonstrated: for instance, operable NSCLC patients randomly assigned to 3 cycles of preoperative durvalumab achieved a significantly lower rate of pathological response compared than those assigned to durvalumab and immunogenic radiotherapy (Altorki N. et al., Lancet Oncology, 2021). To this end, the field is evolving to explore novel radiation startegies including incorporating brachytherapy to generate "hot spots' within the tumor (Jagodinsky C.J. et al., Science Translat Med, 2024), testing different dose rates for RT delivery, and the use of low dose treatment to the gut to modify the microbiome to enhance results of PD-L1blockade in metastatic patients (Chen J et al., Cancer Cell, 2025). More preclinical research as well as clinical trials that incorporate testing these many variables are warranted, to achieve synergy of radiation and immunotherapy."

IO biomarker • Fibrosarcoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Sarcoma • Solid Tumor • CD8 • CXCL16 • CXCR6 • IFNB1 • STING

Subacute cutaneous lupus erythematosus-like drug eruption after durvalumab treatment for squamous cell carcinoma. (PubMed, Dermatol Online J) - "A subacute cutaneous lupus erythematosus-like drug eruption was observed in a patient with durvalumab infusion, with increasing severity after each dose. The eruption improved with cessation of durvalumab, hydroxychloroquine therapy, and sun protection."

Journal • Cutaneous Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus • Oncology • Squamous Cell Carcinoma

ESMO 2024: Treatment of uHCC : Episode 2: Treatment Decisions Based on BLCL Stage (OncLive) - "Panelists discuss current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions."

Video